Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl4

Table 1 Serum function tests

	n	LT (U/L)	AST (U/L)
Control	10	99.50 ± 18.78	244.50 ± 46.52
Model	7	1863.29 ± 893.68a	2680.00 ± 1039.12a
Losartan (20 mg/kg)	7	432.14 ± 112.26d	824.57 ± 265.41d
Losartan (10 mg/kg)	7	535.25 ± 200.78d	77.50 ± 270.32d
Losartan (5 mg/kg)	6	771.71 ± 237.18c	1643.00 ± 810.36

^aP < 0.05 vs control;

^cP < 0.05 vs model;

^dP < 0.01 vs model

Table 2 Serum component of ECM

	n	HA (ng/L)	PC III (μg/L)
Control	10	331.42 ± 42.31	19.06 ± 4.43
Model	7	911.66 ± 345.49a	31.82 ± 6.90a
Losartan (20 mg/kg)	7	425.05 ± 115.80d	22.78 ± 8.38c
Losartan (10 mg/kg)	7	556.11 ± 195.22c	24.49 ± 2.73c
Losartan (5 mg/kg)	6	734.03 ± 318.93c	24.19 ± 6.76

^aP < 0.05 vs control;

^cP < 0.05 vs model;

^dP < 0.01 vs model

Table 3 Degree of fibrosis

	n	0	I	II	III	IV	U-value
Control	10	10	0	0	0	0
Model	7	0	0	1	2	4
Losartan (20 mg/kg)	7	0	2	3	1	1	2.05a
Losartan (10 mg/kg)	8	0	2	4	1	1	2.31a
Losartan (5 mg/kg)	7	0	1	3	2	1	1.49

^aP < 0.05 vs model